Skip to main content
SpringerLink
Log in

Impact of duration and dosage of statin treatment and epicardial fat thickness on the recurrence of atrial fibrillation after electrical cardioversion

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

The purpose of this study was to investigate the time-dependent effect of statin treatment and echocardiographic epicardial fat thickness (EFT) on the maintenance of sinus rhythm (SR) in atrial fibrillation (AF) patients after electrical cardioversion (EC). One hundred sixty-three AF patients without previous statin treatment who underwent EC were consecutively enrolled. The maintenance rate of SR after EC (1, 3, 6, and 12 months) as documented by electrocardiogram and EFT were compared between patients with statin treatment (statin group, n = 63) and those without (no statin group, n = 100). There was no significant difference in the maintenance rate of SR between the groups soon after EC (statin group; 85.7 % vs. no statin; 84.8 %, p = 0.535), after 1 month (71.0 vs. 59.1 %, p = 0.091), and after 3 months (63.2 vs. 50.0 %, p = 0.086). However, the maintenance rate of SR was significantly higher in the statin group compared to no statin group (61.8 vs. 42.9 %, p = 0.024) after 6 months, and this significant difference persisted up to 12 months of follow up (60.1 vs. 36.4 %, p = 0.001). Patients with recurrence showed higher baseline EFT (7.4 ± 2.7 vs. 8.5 ± 3.0 mm, p = 0.014). Multivariate linear regression analysis indicated that EFT, left atrial diameter, high-density lipoprotein cholesterol, statin treatment, and dose were the significant contributors to the maintenance of SR for all periods after EC. Statin treatment and low EFT were associated with a higher maintenance rate of SR in AF patients after EC. Significant benefit of statin was realized 6 months after EC, and this benefit was shown to be maintained over time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 57:e101–e198

    Article  PubMed  Google Scholar 

  2. Naccarelli GV, Varker H, Lin J, Schulman KL (2009) Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 104:1534–1539

    Article  PubMed  Google Scholar 

  3. Tsadok MA, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Pilote L (2012) Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation 126:2680–2687

    Article  PubMed  Google Scholar 

  4. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, Macfarlane PW, PROSPER Executive (2011) Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 342:d1250

    Article  PubMed  Google Scholar 

  5. Kim SS, Knight BP (2009) Electrical and pharmacologic cardioversion for atrial fibrillation. Cardiol Clin 27:95–107

    Article  PubMed  Google Scholar 

  6. Valencia MJ, Climent PVE, Marin OF, Monmeneu MJV, Martinez MJG, Garcia MM, Ibáñez Criado A, De Burgos García F, Rico F, Sogorb Garri F (2002) The efficacy of scheduled cardioversion in atrial fibrillation. Comparison of two schemes of treatment: electrical versus pharmacological cardioversion. Rev Esp Cardiol 55:113–120

    Article  Google Scholar 

  7. Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ, Markowitz SM, Slotwiner DJ, Scheiner MA, Lerman BB (2000) Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 101:1282–1287

    Article  CAS  PubMed  Google Scholar 

  8. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J (2003) Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit 9:RA225–RA229

    CAS  PubMed  Google Scholar 

  9. Ock SY, Cho KI, Kim HJ, Lee NY, Kim EJ, Kim NK, Lee WH, Yeo GE, Heo JJ, Han YJ, Cha TJ (2013) The impacts of C-reactive protein and atrial fibrillation on carotid atherosclerosis and ischemic stroke in patients with suspected ischemic cerebrovascular disease: a single-center retrospective observational cohort study. Korean Circ J 43:796–803

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Soeki T, Bando S, Uematsu E, Matsuura T, Niki T, Ise T, Kusunose K, Hotchi J, Ueda Y, Tomita N, Yamaguchi K, Yagi S, Fukuda D, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Shimabukuro M, Sata M (2013) Pentraxin 3 is a local inflammatory marker in atrial fibrillation. Heart Vessels. doi:10.1007/s00380-013-0400-8

    Google Scholar 

  11. Bambace C, Sepe A, Zoico E, Telesca M, Olioso D, Venturi S, Rossi A, Corzato F, Faccioli S, Cominacini L, Santini F, Zamboni M (2013) Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes. Heart Vessels. doi:10.1007/s00380-012-0315-9

    PubMed  Google Scholar 

  12. Acet H, Ertaş F, Akıl MA, Oylumlu M, Polat N, Yıldız A, Bilik MZ, Yüksel M, Kaya Z, Ulgen MS (2013) New inflammatory predictors for non-valvular atrial fibrillation: echocardiographic epicardial fat thickness and neutrophil to lymphocyte ratio. Int J Cardiovasc Imaging 30(1):81–89

    Article  PubMed  Google Scholar 

  13. Chao TF, Hung CL, Tsao HM, Lin YJ, Yun CH, Lai YH, Chang SL, Lo LW, Hu YF, Tuan TC, Chang HY, Kuo JY, Yeh HI, Wu TJ, Hsieh MH, Yu WC, Chen SA (2013) Epicardial adipose tissue thickness and ablation outcome of atrial fibrillation. PLoS 8(9):e74926

    Article  Google Scholar 

  14. Riesen WF, Engler H, Risch M, Korte W, Noseda G (2002) Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 23:794–799

    Article  CAS  PubMed  Google Scholar 

  15. Siu CW, Lau CP, Tse HF (2003) Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92:1343–1345

    Article  CAS  PubMed  Google Scholar 

  16. Ozaydin M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M, Altinbas A (2006) Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 97:1490–1493

    Article  CAS  PubMed  Google Scholar 

  17. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, Gullestad L (2004) Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 93:780–782

    Article  CAS  PubMed  Google Scholar 

  18. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, Leonetti F (2003) Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 11:304–310

    Article  PubMed  Google Scholar 

  19. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ (2002) Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834–1840

    Article  PubMed  Google Scholar 

  20. Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207–213

    Article  CAS  PubMed  Google Scholar 

  21. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P (1986) Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315:1046–1051

    Article  CAS  PubMed  Google Scholar 

  22. Laufs U, Liao JK (1998) Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho gtpase. J Biol Chem 273:24266–24271

    Article  CAS  PubMed  Google Scholar 

  23. Ganotakis ES, Mikhailidis DP, Vardas PE (2006) Atrial fibrillation, inflammation and statins. Hellenic J Cardiol 47:51–53

    PubMed  Google Scholar 

  24. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S (2003) Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92:1379–1383

    Article  CAS  PubMed  Google Scholar 

  25. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D (2008) Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 51:828–835

    Article  CAS  PubMed  Google Scholar 

  26. Loffredo L, Angelico F, Perri L, Violi F (2012) Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. BMC Cardiovasc Disord 12:107

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Bhardwaj A, Sood NA, Kluger J, Coleman CI (2010) Lack of effect of statins on maintenance of normal sinus rhythm following electrical cardioversion of persistent atrial fibrillation. Int J Clin Pract 64:1116–1120

    Article  CAS  PubMed  Google Scholar 

  28. Demir K, Can I, Koc F, Vatankulu MA, Ayhan S, Akilli H, Aribas A, Alihanoglu Y, Altunkeser BB (2011) Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy. Med Princ Pract 20:464–469

    Article  PubMed  Google Scholar 

  29. Xia W, Yin Z, Li J, Song Y, Qu X (2009) Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol 32:1562–1566

    Article  PubMed  Google Scholar 

  30. Veronese G, Montomoli J, Schmidt M, Horváth-Puhó E, Sørensen HT (2013) Statin use and risk of atrial fibrillation or flutter: a population-based case–control study. Am J Ther. doi:10.1097/MJT.0b013e31827ab488

  31. Deng W, Bukiya AN, Rodríguez-Menchaca AA, Zhang Z, Baumgarten CM, Logothetis DE, Levitan I, Rosenhouse-Dantsker A (2012) Hypercholesterolemia induces up-regulation of KACh cardiac currents via a mechanism independent of phosphatidylinositol 4,5-bisphosphate and Gβγ. J Biol Chem 287:4925–4935

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Nakagomi A, Seino Y, Kohashi K, Kosugi M, Endoh Y, Kusama Y, Atarashi H, Mizuno K (2012) Effects of statin therapy on the production of monocyte pro-inflammatory cytokines, cardiac function, and long-term prognosis in chronic heart failure patients with dyslipidemia. Circ J 76:2130–2138

    Article  CAS  PubMed  Google Scholar 

  33. Annoura M, Ogawa M, Kumagai K, Zhang B, Saku K, Arakawa K (1999) Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology 92:21–27

    Article  CAS  PubMed  Google Scholar 

  34. Diaz-Peromingo JA, Alban-Salgado A, Garcia-Suarez F, Sanchez-Leira J, Saborido-Frojan J, Iglesias-Gallego M (2006) Lipoprotein(a) and lipid profile in patients with atrial fibrillation. Med Sci Monit 12:CR122–CR125

    CAS  PubMed  Google Scholar 

  35. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A, ALLHAT Collaborative Research Group (2009) Atrial fibrillation at baseline and during follow-up in ALLHAT (antihypertensive and lipid-lowering treatment to prevent heart attack trial). J Am Coll Cardiol 54:2023–2031

    Article  CAS  PubMed  Google Scholar 

  36. Schillaci G, Vaudo G, Reboldi G, Verdecchia P, Lupattelli G, Pasqualini L, Porcellati C, Mannarino E (2001) High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens 19:2265–2270

    Article  CAS  PubMed  Google Scholar 

  37. Horio T, Miyazato J, Kamide K, Takiuchi S, Kawano Y (2003) Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens 16:938–944

    Article  CAS  PubMed  Google Scholar 

  38. Watanabe H, Tanabe N, Yagihara N, Watanabe T, Aizawa Y, Kodama M (2011) Association between lipid profile and risk of atrial fibrillation. Circ J 75:2767–2774

    Article  CAS  PubMed  Google Scholar 

  39. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S (2003) Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107:1930–1936

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have no conflict interest.

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea

    Kyoung-Im Cho, Bong-Joon Kim, Tae-Joon Cha, Jung-Ho Heo, Hyun-Su Kim & Jae-Woo Lee

  2. Cardiovascular Research Institute, Kosin University College of Medicine, 34, Amnam-dong, Seo-gu, Busan, 602-702, Korea

    Kyoung-Im Cho, Tae-Joon Cha, Jung-Ho Heo, Hyun-Su Kim & Jae-Woo Lee

Authors
  1. Kyoung-Im Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bong-Joon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tae-Joon Cha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jung-Ho Heo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hyun-Su Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jae-Woo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tae-Joon Cha.

Additional information

K. I. Cho and B. J. Kim should be considered as the first co-authors. These authors contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cho, KI., Kim, BJ., Cha, TJ. et al. Impact of duration and dosage of statin treatment and epicardial fat thickness on the recurrence of atrial fibrillation after electrical cardioversion. Heart Vessels 30, 490–497 (2015). https://doi.org/10.1007/s00380-014-0505-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-014-0505-8

Keywords

Search

Navigation